RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad, the drugs everolimus
and pasireotide have on the patient and on melanoma. Pasireotide is also called SOM-230.
Pasireotide is an experimental drug and is not approved by the Food and Drug Administration.
Everolimus is also called RAD001. Everolimus is approved for use in the U.S. for kidney
cancer. Everolimus is not approved for treatment of melanomas, but early studies show that it
may help some patients with melanoma.